A novel therapeutic approach utilizing our DRQ construct to inhibit dual effects of MIF and D-DT signaling has the potential to treat all progressive brain diseases involving CD74-dependent neuroinflammatory pathways. This evidence concerns the gene MIF and brain disorder.